Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) will host an analysts and investors conference call and webcast on Monday, May 18 at 3:00pm ET. The event will review progress of the Full Market Release of the LIBERTY Endovascular Robotic System and address recent misrepresentations from an unaffiliated third-party article.
Executives will be joined by current LIBERTY users Dr. Charles Briggs and Dr. Zachary Bercu, who will discuss real-world clinical experience and clarify statements previously attributed to them.
Microbot Medical (Nasdaq: MBOT) reported its first commercial revenue from the Limited Market Release of the LIBERTY Endovascular Robotic System in Q1 2026 and has now transitioned to Full Market Release.
By mid-Q2 2026, revenue already exceeded Q1 levels as LIBERTY adoption grew, with hospitals in six U.S. states and more than double the number of accounts since the Limited Market Release ended. The system is being used for diverse procedures, including PAE for BPH, GAE for chronic knee pain and Y-90 radioembolization for liver cancer.
Microbot Medical (Nasdaq: MBOT) reported commercial adoption of the LIBERTY Endovascular Robotic System across multiple accounts, including two sites that participated in the ACCESS-PVI pivotal trial. The company cited growing physician interest after its Full Market Release at SIR and will exhibit at GEST May 14–17, 2026.
Microbot also appointed Alon Tamir as VP Sales, EMEA to support international commercialization efforts.
Microbot Medical (Nasdaq: MBOT) appointed Alon Tamir as Vice President of Sales for EMEA to accelerate commercial readiness for the LIBERTY Endovascular Robotic System.
The company holds FDA clearance (Sept 2025), completed a Limited and Full Market Release in the U.S., and expects a CE mark by end of 2026; Europe procedure volume is cited at ~2.3 million peripheral endovascular procedures.
Microbot Medical (NASDAQ: MBOT) highlighted updated occupational protection guidelines from SIR and CIRSE on April 22, 2026, which address radiation exposure, ergonomic risks and pregnancy protections for interventional staff.
The company positioned its LIBERTY Endovascular Robotic System as a potential solution to reduce radiation exposure and musculoskeletal strain, noting endorsements from at least nine medical societies and an AMA policy adopted in late 2025.
Microbot Medical (Nasdaq: MBOT) will present commercial progress supporting the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference.
The live webcast is April 15, 2026 at 10:15 a.m. ET; management will discuss growth strategy, physician radiation mitigation, staffing benefits, and offer one-on-one investor meetings.
Microbot Medical (Nasdaq: MBOT) has commenced the full market release (FMR) in the U.S. of its LIBERTY® Endovascular Robotic System after a successful limited market release (LMR).
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and has been adopted by leading systems including Emory Healthcare and Tampa General Hospital. The system has been used commercially for PAE, UFE, GAE, Y90 mapping and deliveries, and peripheral arterial interventions. Commercial footprint expanded from 4 to 8 sales territories with a goal of 12 territories by end of 2026.
Microbot Medical (Nasdaq: MBOT) announced that Emory Healthcare completed the first robotic Prostatic Artery Embolization (PAE) and the first robotic Y-90 radioembolization mapping using the LIBERTY® Endovascular Robotic System on March 26, 2026. The single-use, FDA-cleared LIBERTY system aims to improve precision, reduce radiation exposure, and expand access to peripheral endovascular care. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to deepen clinical adoption.
Microbot Medical (NASDAQ: MBOT) announced publication of the ACCESS-PVI pivotal study in the Journal of Vascular and Interventional Radiology on March 24, 2026. The multicenter feasibility study completed in 2025 and underwent independent peer review. The LIBERTY system received FDA clearance in September 2025 and had a limited market release in late 2025, with a planned full market release at the SIR conference in April 2026.
The publication strengthens the clinical evidence base supporting broader commercial adoption of the single-use LIBERTY endovascular robotic system.
Microbot Medical (Nasdaq: MBOT) will present at the 38th Annual Roth Conference March 22-24, 2026, with a live webcast fireside Q&A on March 23, 2026 at 4:00 pm PT. CEO Harel Gadot will discuss LIBERTY commercial progress, limited market release traction, and plans for a full market release in April 2026 at SIR.
The webcast is available via the company’s Investors site and the presentation aims to showcase product differentiation, physician safety benefits, and upcoming commercialization steps.